Spry2 gene expression was found to be lower in a panel of invasive ductal carcinomas compared to normal breast tissue, and lower in HER2-positive (by immunohistochemistry) tumours (Figures 1C and 1D). Here, ERBB2 is linked to invasive ductal breast carcinoma.